Goldman Sachs reports 2.79M shares (5.5%)

Seaport Therapeutics ownership filing: The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC report beneficial ownership of 2,791,814 shares of Seaport Therapeutics Voting Common Stock, representing 5.5% of the class.

Rhea-AI Filing Summary

Seaport Therapeutics ownership filing: The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC report beneficial ownership of 2,791,814 shares of Seaport Therapeutics Voting Common Stock, representing 5.5% of the class. The filing is a joint Schedule 13G filed in early May 2026 and identifies shared voting and dispositive power of 2,791,814 shares held by the reporting entities.

Insights

Institutional Ownership Analyst

Goldman Sachs reports a 5.5% passive stake in Seaport Therapeutics.

The filing shows 2,791,814 shares and lists shared voting and dispositive power held by Goldman Sachs reporting units. The Schedule 13G format indicates a passive/beneficial ownership disclosure rather than an activist or control intent.

Disclosure describes parent/subsidiary structure and limits on attributing client holdings; cash-flow treatment is not stated and timing is limited to the filing date in early May 2026.

Corporate Governance Expert

Joint filing clarifies reporting responsibility and internal attribution.

The exhibits include a joint filing agreement and a parent-subsidiary note that attributes the reported securities to Goldman Sachs Reporting Units. Footnotes disclaim beneficial ownership for certain client accounts and managed entities per the cited Release.

Future amendments or additional schedules may change the public attribution if ownership or voting arrangements change; the filing itself does not indicate any change in control intent.

Key Figures

Schedule 13G filing date: 05/06/2026 Shares beneficially owned: 2,791,814 shares Percent of class: 5.5% +2 more

5 metrics

Schedule 13G filing date 05/06/2026 cover page date for reported position

Shares beneficially owned 2,791,814 shares shared voting and dispositive power reported by Goldman Sachs Reporting Units

Percent of class 5.5% percent of Voting Common Stock reported on the cover information

Sole voting power 0 sole voting power shown as 0 on the cover information

Signatures dated 05/07/2026 signature dates on the joint filing agreement and schedule

Key Terms

Schedule 13G, beneficially owned, shared dispositive power, joint filing agreement

4 terms

Schedule 13G regulatory

"the filing is a joint Schedule 13G filed in early May 2026"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficially owned regulatory

"this filing reflects the securities beneficially owned by certain operating units"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared dispositive power financial

"Shared Dispositive Power 2,791,814.00 shown on the cover page"

joint filing agreement regulatory

"EXHIBIT (99.1) JOINT FILING AGREEMENT is attached to the statement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Goldman Sachs report in SEAPORT THERAPEUTICS (GS)?

Goldman Sachs reports beneficial ownership of 2,791,814 shares, representing 5.5% of Seaport Therapeutics' Voting Common Stock. The amount and percentage are shown on the Schedule 13G cover information dated in early May 2026.

Which Goldman Sachs entities filed the Schedule 13G for SEAPORT THERAPEUTICS?

The filing is made jointly by The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC. A joint filing agreement (Exhibit 99.1) and subsidiary attribution disclosure (Exhibit 99.2) are attached to the schedule.

Does the Schedule 13G indicate Goldman Sachs has sole voting control of the shares?

No. The cover information shows 0 sole voting power and 2,791,814 shared voting power. The filing attributes shared voting and dispositive powers to the reporting units rather than sole control.

Is the reported ownership attributable to client accounts or Goldman Sachs internal units?

The filing states the securities are held by Goldman Sachs Reporting Units and includes footnotes disclaiming beneficial ownership for certain client accounts and managed entities, per the referenced SEC Release guidance.

When was this Schedule 13G filed for SEAPORT THERAPEUTICS?

The cover information and signatures show dates in early May 2026, with signature dates of 05/07/2026 and a cover line dated 05/06/2026 for the reported positions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/11/2026 - 03:19 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

SEAPORT THERAPEUTICS, INC.

(Name of Issuer)

Voting Common Stock, $0.0001 par value per share

(Title of Class of Securities)

81221K108

(CUSIP Number)

05/06/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 81221K108

1

Names of Reporting Persons

THE GOLDMAN SACHS GROUP, INC.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,791,814.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,791,814.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,791,814.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.5 %

12

Type of Reporting Person (See Instructions)

HC, CO

SCHEDULE 13G

CUSIP Number(s): 81221K108

1

Names of Reporting Persons

GOLDMAN SACHS & CO. LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,791,814.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,791,814.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,791,814.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.5 %

12

Type of Reporting Person (See Instructions)

BD, OO, IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: SEAPORT THERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 101 SEAPORT BLVD., Floor 12, Boston, X1, 02210
Item 2.
(a)	Name of person filing: THE GOLDMAN SACHS GROUP, INC.| GOLDMAN SACHS & CO. LLC
(b)	Address or principal business office or, if none, residence: The Goldman Sachs Group, Inc. 200 West Street New York, NY 10282| Goldman Sachs & Co. LLC 200 West Street New York, NY 10282
(c)	Citizenship: THE GOLDMAN SACHS GROUP, INC. - Delaware| GOLDMAN SACHS & CO. LLC - New York
(d)	Title of class of securities: Voting Common Stock, $0.0001 par value per share
(e)	CUSIP Number(s): 81221K108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: See the response(s)to Item 11 on the attached cover page(s).
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit (99.2)
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

THE GOLDMAN SACHS GROUP, INC.

Signature:	Name: Abhilasha Bareja
Name/Title:	Attorney-in-fact
Date:	05/07/2026

GOLDMAN SACHS & CO. LLC

Signature:	Name: Abhilasha Bareja
Name/Title:	Attorney-in-fact
Date:	05/07/2026

Exhibit Information

EXHIBIT (99.1) JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Voting Common Stock, $0.0001 par value per share, of SEAPORT THERAPEUTICS, INC. and further agree to the filing of this agreement as an Exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G. Date: 05/07/2026 THE GOLDMAN SACHS GROUP, INC. By:/s/ Abhilasha Bareja ---------------------------------------- Name: Abhilasha Bareja Title: Attorney-in-fact GOLDMAN SACHS & CO. LLC By:/s/ Abhilasha Bareja ---------------------------------------- Name: Abhilasha Bareja Title: Attorney-in-fact EXHIBIT (99.2) ITEM 7 INFORMATION The securities being reported on by The Goldman Sachs Group, Inc. ("GS Group"), as a parent holding company, are owned, or may be deemed to be beneficially owned, by Goldman Sachs & Co. LLC ("Goldman Sachs"), a broker or dealer registered under Section 15 of the Act and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940. Goldman Sachs is a subsidiary of GS Group. EXHIBIT (99.3) ITEM 4 INFORMATION *In accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned by certain operating units (collectively, the "Goldman Sachs Reporting Units") of The Goldman Sachs Group, Inc. and its subsidiaries and affiliates (collectively, "GSG"). This filing does not reflect securities, if any, beneficially owned by any operating units of GSG whose ownership of securities is disaggregated from that of the Goldman Sachs Reporting Units in accordance with the Release. The Goldman Sachs Reporting Units disclaim beneficial ownership of the securities beneficially owned by (i) any client accounts with respect to which the Goldman Sachs Reporting Units or their employees have voting or investment discretion or both, or with respect to which there are limits on their voting or investment authority or both and (ii) certain investment entities of which the Goldman Sachs Reporting Units act as the general partner, managing general partner or other manager, to the extent interests in such entities are held by persons other than the Goldman Sachs Reporting Units. ****Please update the footnotes here****